Jump Financial LLC Invests $1.56 Million in ANI Pharmaceuticals, Inc. $ANIP

Key Points

• Jump Financial LLC made a new investment of approximately $1.56 million in ANI Pharmaceuticals, acquiring 23,221 shares during the first quarter.
• Analysts have a generally positive outlook for ANI Pharmaceuticals, with several firms, including HC Wainwright and Guggenheim, maintaining buy ratings and increasing their target prices for the stock.
• ANI Pharmaceuticals reported earnings of $1.80 per share for the last quarter, exceeding analyst expectations, and showed a year-over-year revenue increase of 53.2%.

Jump Financial LLC acquired a new stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 23,221 shares of the specialty pharmaceutical company's stock, valued at approximately $1,555,000. Jump Financial LLC owned about 0.11% of ANI Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. National Bank of Canada FI bought a new position in ANI Pharmaceuticals in the first quarter valued at approximately $79,000. GAMMA Investing LLC boosted its stake in ANI Pharmaceuticals by 163.8% in the first quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company's stock valued at $95,000 after acquiring an additional 881 shares during the last quarter. Rafferty Asset Management LLC bought a new position in ANI Pharmaceuticals in the fourth quarter valued at approximately $200,000. Bridgefront Capital LLC bought a new position in ANI Pharmaceuticals in the fourth quarter valued at approximately $204,000. Finally, Mesirow Financial Investment Management Inc. bought a new position in ANI Pharmaceuticals in the first quarter valued at approximately $206,000. 76.05% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on ANIP shares. Truist Financial lifted their price target on shares of ANI Pharmaceuticals from $65.00 to $77.00 and gave the stock a "hold" rating in a research report on Monday, August 11th. HC Wainwright reissued a "buy" rating and set a $93.00 price target (up from $84.00) on shares of ANI Pharmaceuticals in a research report on Friday, August 8th. Zacks Research raised shares of ANI Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 21st. Wall Street Zen raised shares of ANI Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 16th. Finally, Guggenheim restated a "buy" rating and set a $86.00 price objective on shares of ANI Pharmaceuticals in a report on Monday, May 12th. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $84.75.

Insider Buying and Selling at ANI Pharmaceuticals

In related news, SVP Krista Davis sold 1,763 shares of ANI Pharmaceuticals stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $91.10, for a total transaction of $160,609.30. Following the completion of the sale, the senior vice president owned 62,896 shares of the company's stock, valued at approximately $5,729,825.60. The trade was a 2.73% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Antonio R. Pera sold 5,421 shares of the business's stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $89.73, for a total transaction of $486,426.33. Following the completion of the transaction, the director owned 29,952 shares of the company's stock, valued at $2,687,592.96. The trade was a 15.33% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 405,538 shares of company stock worth $35,690,131 in the last ninety days. Insiders own 12.70% of the company's stock.

ANI Pharmaceuticals Stock Up 1.0%

ANIP stock traded up $0.97 during midday trading on Friday, hitting $93.50. The company's stock had a trading volume of 283,240 shares, compared to its average volume of 749,580. The company has a debt-to-equity ratio of 1.39, a current ratio of 2.54 and a quick ratio of 1.96. ANI Pharmaceuticals, Inc. has a twelve month low of $52.50 and a twelve month high of $93.72. The company's fifty day moving average price is $73.39 and its 200 day moving average price is $67.12. The stock has a market capitalization of $2.03 billion, a P/E ratio of -121.43 and a beta of 0.63.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its quarterly earnings results on Friday, August 8th. The specialty pharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.42 by $0.38. The firm had revenue of $211.37 million for the quarter, compared to analyst estimates of $187.18 million. ANI Pharmaceuticals had a negative net margin of 1.37% and a positive return on equity of 25.03%. The company's revenue was up 53.2% compared to the same quarter last year. During the same period in the previous year, the business earned $1.02 EPS. As a group, equities research analysts predict that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.